ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

KIN Kindred Biosciences Inc

9.25
0.00 (0.00%)
26 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Kindred Biosciences Inc NASDAQ:KIN NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 9.25 9.24 9.26 0 01:00:00

Kindred Biosciences to Present at 2016 Ladenburg Thalmann Healthcare Conference

20/09/2016 9:01pm

PR Newswire (US)


Kindred Biosciences (NASDAQ:KIN)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Kindred Biosciences Charts.

SAN FRANCISCO, Sept. 20, 2016 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced Dr. Richard Chin, President and CEO, will be presenting at the Ladenburg Thalmann Healthcare Conference in New York City on Tuesday, September 27, 2016 at 11:00 AM EDT. The conference is being held at the Sofitel Hotel.

The presentation will be available via a live webcast at the following URL: http://wsw.com/webcast/ladenburg2/kin.

An archived version of the webcast and presentation will be available for 30 days on the Company's website: http://kindredbio.com/investor-relations/events.

About Kindred Biosciences, Inc. 

Kindred Biosciences is a development-stage biopharmaceutical company focused on saving and improving the lives of pets.  Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy.  The Company's strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses.  The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes.

For more information or to download the corporate presentation, visit www.KindredBio.com/LearnMore. Stay connected with KindredBio on Facebook at www.Facebook.com/KindredBio.

Contact

Russell Radefeld
KindredBio
Russell.radefeld@kindredbio.com 
(650) 701-7904

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/kindred-biosciences-to-present-at-2016-ladenburg-thalmann-healthcare-conference-300330646.html

SOURCE Kindred Biosciences, Inc.

Copyright 2016 PR Newswire

1 Year Kindred Biosciences Chart

1 Year Kindred Biosciences Chart

1 Month Kindred Biosciences Chart

1 Month Kindred Biosciences Chart

Your Recent History

Delayed Upgrade Clock